atorvastatin has been researched along with Atheroma in 141 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 121 (85.82) | 24.3611 |
| 2020's | 20 (14.18) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q | 2 |
| Gao, F; Ma, XT; Shen, H; Wang, ZJ; Yang, LX; Zhou, YJ | 1 |
| Busk, M; Bøtker, HE; Dey, D; Fonte, T; Grove, EL; Hosbond, S; Iraqi, N; Jensen, JM; Leipsic, J; Mathiassen, ON; Mortensen, MB; Narula, J; Nørgaard, BL; Sand, NP; Updegrove, A | 1 |
| Cinque, G; Dowling, LM; Njoroge, W; Sulé-Suso, J; Xie, B; Yang, Y | 1 |
| Huang, J; Shi, R; Wang, X; You, B; Zhang, G; Zhao, M; Zhou, M | 1 |
| Huang, H; Lu, C; Luo, T; Wu, Q; Xiong, S; Xiong, Y; Zeng, J; Zhang, Z | 1 |
| Du, W; Han, B; Hou, J; Hou, S; Huang, X; Liu, D; Liu, Q; Lv, H; Nie, H; Sun, Y; Wang, G; Wang, X; Yang, M; Yu, B; Zhang, L; Zhang, R | 1 |
| Assali, M; Berus, JM; Ceneri, N; Choudhary, G; Christensen, JL; Dong, W; Healy, A; Lee, C; Mantsounga, C; Morrison, AR; Neverson, J; Nilson, R; Watts, JP; Wu, WC | 1 |
| Bai, Y; Deng, J; Hao, H; Huang, Y; Li, S; Meng, L; Nan, D; Peng, Q; Shen, Z; Yu, W; Yu, Z | 1 |
| Agnew, D; Arora, R; Hossaini Nasr, S; Huang, X; Kauffman, N; Parameswaran, N; Qian, C; Ramadan, S; Rashidijahanabad, Z; Zinn, KR | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Chen, MF; Chien, KL; Hsu, HC; Lee, YT; Lin, HJ; Lu, TP; Su, TC; Yu, SL | 1 |
| Bender, K; Bonaterra, GA; Kelber, O; Kinscherf, R; Metz, J; Metz, S; Schwarzbach, H; Weiser, D; Wilhelm, B | 1 |
| Cao, X; Chen, Y; Huang, X; Li, Y; Wu, L; Xiao, H; Zhou, X | 1 |
| Bode, C; Boettler, T; Dederichs, TS; Dufner, B; Ehlert, CA; Härdtner, C; Heidt, T; Hilgendorf, I; Ho-Tin-Noé, B; Hoppe, N; Jander, A; Kaeser, R; Kohl, P; Kornemann, J; Krebs, K; Madl, J; Pieterman, EJ; Princen, HMG; Rauterberg, S; Robbins, CS; Sharipova, D; Stachon, P; Starz, C; Swirski, FK; von Zur Mühlen, C; Willecke, F; Wolf, D; Zirlik, A; Zou, J | 1 |
| Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, EA; Quax, PHA; Voorham, W | 1 |
| Hoogeveen, RM; Kaiser, Y; Kroon, J; Moens, SJB; Stroes, ESG; Verberne, HJ; Verweij, SL; Vogt, L | 1 |
| Chen, T; Demuyakor, A; Feng, X; Gao, Z; Hou, J; Hu, S; Jia, H; Liu, H; Qin, Y; Weng, Z; Xu, M; Xu, Y; Yu, B; Zeng, M; Zhang, S; Zhao, C | 1 |
| Ha, K; Han, SH; Jang, AY; Kang, WC; Kim, M; Lee, K; Moon, J; Oh, PC; Suh, SY | 1 |
| Hellberg, S; Jauhiainen, M; Knuuti, J; Liljenbäck, H; Metso, J; Nuutila, P; Roivainen, A; Saraste, A; Saukko, P; Savisto, N; Silvola, JMU; Sippola, S; Ståhle, M; Virta, J; Ylä-Herttuala, S | 1 |
| Fang, ZF; Guo, Y; Li, XP; Long, JK; Luo, F; Peng, DQ; Ruan, GY; Xia, Q; Zhao, SP; Zheng, XL | 1 |
| Liu, HY; Tang, Y; Tong, H; Wang, XF; Zhou, J; Zhou, QC | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 1 |
| Arsenault, BJ; Ballantyne, CM; Barter, P; Chapman, MJ; Erbel, R; Hoogeveen, RC; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M | 1 |
| Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW | 1 |
| Adamova, IYU; Afanasieva, OI; Balakhonova, TV; Ezhov, MV; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS | 1 |
| Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Fusazaki, T; Ishikawa, Y; Itoh, T; Morino, Y; Nakajima, S; Nakamura, M; Satoh, M; Sugawara, S | 1 |
| Chen, XH; Deng, YQ; Tan, Y; Wu, FL; Wu, XM; Yang, DJ; Zhang, XW; Zhou, F | 1 |
| An, F; Li, D; Li, X; Liu, D; Liu, H; Pan, J; Tian, J; Wang, X; Zhang, M | 1 |
| Cao, W; Cao, Z; Chen, X; Cheng, J; Gao, W; Guo, S; Jiang, Y; Li, B; Li, M; Li, Q; Li, X; Li, Z; Peng, C; Shen, J; Sun, J; Sun, X; Tian, F; Tian, Y; Tian, Z; Wang, H; Wang, P; Wang, T; Wang, W; Wang, Y; Yang, J; Yang, Y; Yao, J; Zhang, Z; Zhao, X; Zhou, Q | 1 |
| Gao, H; He, J; Jiang, C; Liu, J; Lu, J; Yang, H; Zhang, W; Zhao, Y | 1 |
| Chen, Y; Guo, Y; Jiang, XH; Li, YJ; Liu, SS; Ruan, CX; Wang, YJ; Weng, XG; Yang, Q; Zhou, BB; Zhu, XX | 1 |
| Abbasi, A; Bahrami, M; Farhad, N; Froushani, SMA; Zarei, L | 1 |
| Chen, X; Cui, H; He, F; Hu, Y; Ju, J; Wang, S; Ye, H | 1 |
| Liu, G; Liu, M; Wang, M | 1 |
| Baomin, Z; Houshuai, T; Liping, Z; Tao, Y; Xiufang, L | 1 |
| Guan, S; Li, W; Wang, B; Zhang, Y | 1 |
| Guo, X; Li, X; Wang, L; Wang, P; Xia, X | 1 |
| Bai, QK; Deng, SH; Jiang, Q; Jiang, XZ; Zhang, Y; Zhang, ZP; Zhu, YC | 1 |
| Jang, IK; Kim, HO; Kurihara, O; Lee, H; Minami, Y; Russo, M; Soeda, T; Thondapu, V; Yonetsu, T | 1 |
| Christodoulou, E; Kadoglou, NPE; Kakisis, J; Kostomitsopoulos, NG; Liapis, CD; Paronis, E; Stasinopoulou, M; Valsami, G | 1 |
| Cardozo, KHM; Carvalho, VM; Dariolli, R; Krieger, JE; Laurindo, FR; Malagrino, PA; Padilha, K; Pereira, ADC; Tanaka, LY; Venturini, G | 1 |
| Cao, Z; Jin, H; Li, B; Liu, M; Shen, Z; Sun, X; Tian, Y; Zhang, T; Zhang, Z; Zhao, X | 1 |
| Doshi, R; Kumar, A; Shariff, M | 1 |
| Lee, CW; Park, SJ | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Delgado, G; Naves, M | 1 |
| Bremer, C; Demmer, P; Frenzel, T; Hahnenkamp, A; Immenschuh, S; Larmann, J; Schmitz, M; Theilmeier, G; Tietge, UJ | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Guo, RW; Heng, XH; Qi, F; Si, YK; Yang, LX; Zhou, XB | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G | 1 |
| Gao, J; Gao, X; Pan, S | 1 |
| Abdelbaky, A; Alon, A; Beals, CR; Dansky, H; Farkouh, ME; Fayad, ZA; Klimas, MT; Mogg, R; Nunes, IO; Rudd, JH; Shankar, SS; Subramanian, SS; Tawakol, A | 1 |
| Gerber, BL | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| de Graaf, MA; Jukema, JW | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Davoodpour, P; Larsson, L; Malm, J; Mörk, LM; Norata, GD; Parini, P; Rehnmark, S; Witt, MR | 1 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Fang, D; Jia, H; Qu, Z; Quan, W; Quan, Z; Yang, S | 1 |
| Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Kawahara, T; Suzuki, G | 1 |
| Cai, Z; He, B; Hu, L; Jin, S; Li, D; Nie, P; Shao, Q; Shen, J; Shen, L; Xiao, H; Yi, J; Yu, Y | 1 |
| Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Ashrafi, A | 1 |
| Guo, P; Luan, H; Sun, X; Wang, S; Wu, C; Zhang, X | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Asrar Ul Haq, M; Mutha, V; Rudd, N; Subiakto, I; Van Gaal, WJ | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katsimpoulas, M; Kostakis, A; Kostomitsopoulos, N; Liapis, CD; Moustardas, P | 1 |
| Ai, R; Chen, F; Li, G; Lu, WH; Tang, ZZ; Wu, XW | 1 |
| Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C | 1 |
| Moreno, PR | 1 |
| Akagi, H; Akasaka, T; Imanishi, T; Ino, Y; Kitabata, H; Komukai, K; Kubo, T; Kumiko, H; Matsuo, Y; Okumoto, Y; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Takarada, S; Tanaka, A; Tanimoto, T; Ueno, S; Yamaguchi, T; Yamano, T | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Ono, T; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Chen, M; Huang, BT | 1 |
| Nicholls, SJ; Puri, R; Shao, M; Stegman, B | 1 |
| Abdelbaky, A; Ballantyne, CM; Du, S; Ehlgen, A; Emami, H; Farkouh, ME; Farmer, M; Fayad, ZA; Hayes, W; Kim, J; Langenickel, TH; Li, L; Mohler, ER; Roth, E; Subramanian, S; Tawakol, A; Velasquez, L; Vucic, E | 1 |
| Deng, L; Gong, L; Li, D; Li, Y; Qi, C; Wu, W; Zhang, C; Zhang, Q; Zhang, T; Zhang, Y | 1 |
| Rajamannan, NM | 1 |
| Brinkmann, SJ; Buijs, N; Couderc, R; Cynober, L; Richir, M; van Leeuwen, PA; Wörner, EA | 1 |
| Hongcheng, F; Ming, D; Shaoyuan, C; Yulang, H | 1 |
| Callies, S; Demmer, P; Hu, N; Janssen, H; Larmann, J; Loghmani-khouzani, H; Schuett, H; Sölter, G; Theilmeier, G; Tietge, UJ; Wagner, CS; Warnecke, G | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 3 |
| Cai, X; Ding, J; Li, B; Qian, C; Wang, Y; Wei, B; Wu, H | 1 |
| Abbara, S; Fitch, KV; Grinspoon, SK; Hoffmann, U; Hwang, J; Ihenachor, EJ; Lo, J; Looby, SE; Lu, MT; Oh, J; Plutzky, J; Robbins, G; Tawakol, A; Wei, J; Zimmerman, CO | 1 |
| De Meyer, GR; Martinet, W; Rombouts, M; Roth, L; Schrijvers, DM | 1 |
| Hou, R; Ma, A; Pan, X; Wang, T; Wu, M; Xiao, X; Yang, S; Zhu, X | 1 |
| Chen, Z; Jia, F; Lu, G; Sun, J; Wu, C | 1 |
| Aguirre, A; Cho, YS; Fujimoto, JG; Jang, IK; Jia, H; Lee, H; Minami, Y; Soeda, T; Vergallo, R; Wang, Z; Xing, L; Yu, B | 1 |
| Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Minami, Y; Soeda, T; Vergallo, R; Xing, L; Yu, B; Zhang, S | 1 |
| Gao, J; Gao, X; Pan, S; Zhao, Z | 1 |
| Chen, Y; Han, H; Ni, J; Sun, J; Zhang, R; Zhu, J | 1 |
| Chen, Z; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Lopez, JJ; Skalicka, H; Sonka, M; Wahle, A; Zhang, L | 1 |
| Frostegård, J; Liu, A; Sun, J; Yan, K; Zhang, Y | 1 |
| Cho, L; Elshazly, M; Kapadia, S; King, P; Nicholls, SJ; Nissen, SE; Puri, R; Shao, M; Stegman, B; Tuzcu, M | 1 |
| Chen, W; Cheng, J; Chiu, B | 1 |
| Chen, Y; Duan, Y; Han, J; Li, Q; Li, X; Li, Y; Liu, Y; Ma, C; Sun, L; Tan, H; Wang, Y; Yang, X; Zhao, B | 1 |
| Feldman, MD; Hoyt, T; Jang, IK; Lee, H; Milner, TE; Minami, Y; Phipps, JE; Xing, L; Yu, B | 1 |
| Dai, J; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Minami, Y; Ong, D; Soeda, T; Vergallo, R; Xing, L; Yu, B; Zhang, S | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G | 1 |
| Andersson, KE; Eussen, SR; Garssen, J; Hellstrand, P; Klungel, OH; Oste, R; Rompelberg, CJ; van Kranen, H | 1 |
| Ascaso, JF; Lorente, R; Martínez-Hervás, S; Molina, M; Navarro-Hidalgo, MI; Priego, A; Real, JT | 1 |
| Andrys, C; Brcakova, E; Micuda, S; Mullerova, Z; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Kawaguchi, R | 1 |
| Saito, Y | 1 |
| Chapman, MJ | 1 |
| Takagi, H; Umemoto, T | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Miyauchi, K | 1 |
| Hasebe, N; Ota, H; Takeuchi, T | 1 |
| Chan, CW; Chan, KK; Chan, PH; Chan, RH; Hau, WK; Kong, SL; Lam, SC; Lam, YM; Lee, SW; Tam, FC; Tse, HF; Wong, MK | 1 |
| Brown, K; Bucerius, J; Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Kotsuma, M; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Ramachandran, S; Roytman, M; Rudd, JH; Tanimoto, T; Tsimikas, S; Vucic, E | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S | 1 |
| Fujii, K; Masuyama, T | 1 |
| Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Guo, R; Heng, X; Liang, X; Shi, Y; Yang, L; Zhou, X | 1 |
9 review(s) available for atorvastatin and Atheroma
| Article | Year |
|---|---|
Effect of pitavastatin and atorvastatin on regression of atherosclerosis assessed using intravascular ultrasound: a meta-analysis.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome; Ultrasonography, Interventional | 2018 |
Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials.
Topics: Atorvastatin; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention | 2020 |
Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Rosuvastatin Calcium; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Plaque, Atherosclerotic; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis | 2012 |
The role of endoglin in atherosclerosis.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
47 trial(s) available for atorvastatin and Atheroma
| Article | Year |
|---|---|
Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Humans; Male; Middle Aged; PCSK9 Inhibitors; Plaque, Atherosclerotic; Proprotein Convertase 9; Rosuvastatin Calcium; Tomography, Optical Coherence | 2021 |
Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study.
Topics: Angina, Stable; Atorvastatin; Ezetimibe; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Tomography, X-Ray Computed | 2022 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Plaque, Atherosclerotic; Quinolines; Taiwan | 2020 |
Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lower Extremity; Male; Middle Aged; Plaque, Atherosclerotic; Quinolines; Treatment Outcome | 2021 |
Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Spectroscopy, Near-Infrared; Ultrasonography, Interventional | 2021 |
Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Color; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Plaque, Atherosclerotic; Proportional Hazards Models; Rosuvastatin Calcium; Ultrasonography | 2017 |
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Topics: Atorvastatin; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipoprotein(a); Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2018 |
Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Tomography, Optical Coherence | 2018 |
Comparison and analysis of the therapeutic effect of different statins in the treatment of atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Pravastatin; Simvastatin | 2018 |
Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography.
Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Carotid Arteries; Carotid Artery Diseases; China; Cholesterol, LDL; Contrast Media; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neovascularization, Pathologic; Phospholipids; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Sulfur Hexafluoride; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color | 2019 |
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Treatment Outcome | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
[Series: Clinical study from Japan and its reflections; atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Aorta; Atorvastatin; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarc
Topics: Anti-Arrhythmia Agents; Atorvastatin; Benzazepines; Biomarkers; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Emergencies; Femoral Neck Fractures; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Middle Aged; Myocardial Infarction; Orthopedic Procedures; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Research Design; Risk Factors; Severity of Illness Index; Tachycardia, Ventricular; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2014 |
The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diet, High-Fat; Elastin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Physical Conditioning, Animal; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2014 |
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography | 2015 |
Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Tomography, Optical Coherence | 2014 |
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Ultrasonography, Interventional | 2015 |
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multimodal Imaging; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazines; United States | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Amino Acids; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Treatment Outcome | 2015 |
Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study.
Topics: Aged; Algorithms; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2016 |
Serial Optical Coherence Tomography and Intravascular Ultrasound Analysis of Gender Difference in Changes of Plaque Phenotype in Response to Lipid-Lowering Therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Reproducibility of Results; Sex Factors; Single-Blind Method; Time Factors; Tomography, Optical Coherence; Ultrasonography, Interventional | 2016 |
Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Prospective Studies; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Time Factors; Ultrasonography, Interventional; User-Computer Interface | 2017 |
Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Sex Factors; Treatment Outcome; Young Adult | 2016 |
Lipid-lowering therapy stabilizes the complexity of non-culprit plaques in human coronary artery: a quantitative assessment using OCT bright spot algorithm.
Topics: Aged; Algorithms; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; China; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Rosuvastatin Calcium; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional; Young Adult | 2017 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors | 2012 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
87 other study(ies) available for atorvastatin and Atheroma
| Article | Year |
|---|---|
Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Matrix Metalloproteinase 9; Pioglitazone; Plaque, Atherosclerotic; Rabbits; Triglycerides | 2022 |
Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Calcium; Disease Models, Animal; Fluorine Radioisotopes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Rabbits; Radiopharmaceuticals; Sodium Fluoride; Vascular Calcification | 2021 |
Detection of lipid efflux from foam cell models using a label-free infrared method.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol; Foam Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic | 2022 |
Desipramine enhances the stability of atherosclerotic plaque in rabbits monitored with molecular imaging.
Topics: Animals; Atherosclerosis; Atorvastatin; Desipramine; Molecular Imaging; Plaque, Atherosclerotic; Rabbits | 2023 |
Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation.
Topics: Animals; Atherosclerosis; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Mice; Plaque, Atherosclerotic | 2023 |
Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Nucleus; Gene Silencing; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; Male; Methotrexate; Mice, Inbred C57BL; Models, Biological; Phosphorylation; Plaque, Atherosclerotic; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2019 |
Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification.
Topics: Aged; Animals; Atherosclerosis; Atorvastatin; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Macrophages; Male; Mice, Knockout, ApoE; Neuropeptides; Plaque, Atherosclerotic; Prenylation; rac1 GTP-Binding Protein; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Retrospective Studies; rho Guanine Nucleotide Dissociation Inhibitor alpha; Signal Transduction; Vascular Calcification | 2020 |
Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biological Transport; Ceramides; Fatty Acids, Monounsaturated; Glycosphingolipids; Immunosuppressive Agents; Lipid Metabolism; Lipids; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Plaque, Atherosclerotic; Vasculitis | 2020 |
Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atorvastatin; Drug Delivery Systems; Hyaluronan Receptors; Hyaluronic Acid; Inflammation; Macrophages; Mice; Mice, Knockout; Nanoparticles; Plaque, Atherosclerotic; RAW 264.7 Cells | 2020 |
Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Rabbits; Time Factors | 2020 |
Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering.
Topics: Animals; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Biomarkers; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diet, Fat-Restricted; Disease Models, Animal; Down-Regulation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Receptors, LDL | 2020 |
Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization.
Topics: Angiopoietin-2; Animals; Antigens, CD; Apolipoprotein E3; Atorvastatin; Cadherins; Cholesterol, Dietary; Male; Mice; Mice, Mutant Strains; Neovascularization, Pathologic; Plaque, Atherosclerotic | 2021 |
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.
Topics: Aged; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Female; Fluorodeoxyglucose F18; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Renal Insufficiency, Chronic; Risk Factors | 2021 |
Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging.
Topics: Atorvastatin; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Plaque, Atherosclerotic; Rosuvastatin Calcium; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Topics: Animal Feed; Animals; Aortic Diseases; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, LDL; Time Factors | 2017 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Models, Animal; Gene Expression; Immunohistochemistry; Lipid Metabolism; Male; Metformin; Plaque, Atherosclerotic; Rabbits | 2017 |
Quantitative evaluation of atherosclerotic plaques and intraplaque neovascularization using contrast-enhanced ultrasound after treatment with atorvastatin in rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Contrast Media; Neovascularization, Pathologic; Plaque, Atherosclerotic; Rabbits; Ultrasonography | 2017 |
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley | 2018 |
Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
Topics: Animals; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Receptor for Advanced Glycation End Products | 2018 |
Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Aortic Diseases; Apoptosis; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Peripheral Arterial Disease; Pilot Projects; Plaque, Atherosclerotic; Rabbits; Time Factors; Treatment Outcome; Ultrasonic Therapy | 2019 |
Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques.
Topics: Animals; Atorvastatin; Cholesterol; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice, Knockout, ApoE; Nanoparticles; Phosphatidylethanolamines; Plaque, Atherosclerotic; Polylactic Acid-Polyglycolic Acid Copolymer; RNA, Small Interfering; Scavenger Receptors, Class E; THP-1 Cells | 2018 |
[Establishment of vulnerable plaque model by mast cell activation in adventitia and evaluation of effectiveness of intervention of Shenlian tablet].
Topics: Adventitia; Animals; Atorvastatin; C-Reactive Protein; Cell Degranulation; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Histamine; Interleukin-1beta; Lipoproteins, HDL; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice, Knockout, ApoE; NF-kappa B; Plaque, Atherosclerotic; Random Allocation; Rats; Tablets | 2016 |
All-trans retinoic acid effectively reduces atheroma plaque size in a rabbit model of high-fat-induced atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Diet, High-Fat; Hypercholesterolemia; Lipids; Plaque, Atherosclerotic; Rabbits; Random Allocation; Tretinoin; Tunica Intima | 2018 |
Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium | 2018 |
Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD.
Topics: Atorvastatin; Cardiovascular Diseases; Computed Tomography Angiography; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2019 |
Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol; Cytokines; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Probucol | 2019 |
Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization.
Topics: Atorvastatin; Biomarkers; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Rosuvastatin Calcium; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2019 |
Statins' Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model-A "Rebound" Stimulation of Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Collagen; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Rupture, Spontaneous; Signal Transduction; Time Factors | 2019 |
Integrated proteomics and metabolomics analysis reveals differential lipid metabolism in human umbilical vein endothelial cells under high and low shear stress.
Topics: Atherosclerosis; Atorvastatin; Cells, Cultured; Cholesterol; Glycosylation; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipidomics; Mechanotransduction, Cellular; Phenotype; Plaque, Atherosclerotic; Protein Processing, Post-Translational; Proteomics; Receptors, LDL; Regional Blood Flow; Stress, Mechanical | 2019 |
Membrane-permeabilized sonodynamic therapy enhances drug delivery into macrophages.
Topics: Atherosclerosis; Atorvastatin; Calcium; Cell Line; Cell Membrane; Cell Membrane Permeability; Cell Survival; Cholesterol; Foam Cells; Humans; Lipid Droplets; Macrophages; Membrane Potential, Mitochondrial; Plaque, Atherosclerotic; Protoporphyrins; Reactive Oxygen Species; THP-1 Cells; Ultrasonic Therapy | 2019 |
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography | 2014 |
In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Arteries; Atorvastatin; Cell Migration Assays, Macrophage; Cells, Cultured; Diet; Fluorescence; Green Fluorescent Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Tomography | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arachidonate 5-Lipoxygenase; Atherosclerosis; Atorvastatin; Chemokine CCL3; Cholesterol, Dietary; Down-Regulation; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotrienes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Signal Transduction | 2013 |
Effect of minocycline on carotid atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Minocycline; Plaque, Atherosclerotic; Pyrroles; Rabbits | 2013 |
In vivo evaluation of atherosclerotic plaque inflammation and of anti-inflammatory effects of statins by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima | 2013 |
The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cytokines; Disease Models, Animal; Drug Synergism; Feces; Heptanoic Acids; Male; Mice; Mice, Knockout; Molecular Mimicry; Plaque, Atherosclerotic; Pyrroles; Thyroid Hormones | 2013 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Atorvastatin; Diet, High-Fat; Gene Expression Regulation; Heptanoic Acids; NF-kappa B; Plaque, Atherosclerotic; Pyrroles; Rabbits; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2014 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors.
Topics: Animals; Apolipoproteins E; Atorvastatin; Chemokines; Collagenases; Heptanoic Acids; Macrophages; Mice; Mice, Knockout; Monocytes; Plaque, Atherosclerotic; Pyrroles; Receptors, Chemokine; Time Factors | 2014 |
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction | 2014 |
Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Plaque, Atherosclerotic; Porphyromonas gingivalis; Pyrroles; Rabbits; Vascular Cell Adhesion Molecule-1 | 2014 |
Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Caffeic Acids; Cell Line; Chlorogenic Acid; Cholesterol; Cholesterol, LDL; Coumaric Acids; Diet, High-Fat; Gallic Acid; Gene Expression; Lipoproteins; Lipoproteins, LDL; Liver X Receptors; Macrophages; Mice; Mice, Knockout; Orphan Nuclear Receptors; Plaque, Atherosclerotic; PPAR gamma; Triglycerides; Vasodilation | 2014 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; gamma-Glutamyltransferase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Strengthening the Achilles heel of high-risk plaques.
Topics: Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Tomography, Optical Coherence | 2014 |
Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; CD40 Ligand; Cholesterol; Contrast Media; Dextrans; Diet, High-Fat; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; Succimer; Transgenes; Tumor Suppressor Protein p53 | 2015 |
Atorvastatin Attenuates Bone Loss and Aortic Valve Atheroma in LDLR Mice.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cholesterol, Dietary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Mice; Osteogenesis; Osteoporosis; Plaque, Atherosclerotic; X-Ray Microtomography | 2015 |
The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.
Topics: Animals; Anticholesteremic Agents; Arginine; Atorvastatin; Cholesterol; Dietary Supplements; Hypercholesterolemia; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Rabbits | 2015 |
Increased IL-37 in Atherosclerotic Disease could be Suppressed by Atorvastatin Therapy.
Topics: Animals; Atherosclerosis; Atorvastatin; Foam Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Male; Plaque, Atherosclerotic; Rabbits; RNA, Messenger; Smad3 Protein | 2015 |
Acute perioperative-stress-induced increase of atherosclerotic plaque volume and vulnerability to rupture in apolipoprotein-E-deficient mice is amenable to statin treatment and IL-6 inhibition.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Laparotomy; Lipoproteins; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Perioperative Period; Plaque, Atherosclerotic; Rupture; Serum Amyloid A Protein; Signal Transduction | 2015 |
Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
Topics: Animal Feed; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Fibrillin-1; Hypercholesterolemia; Kaplan-Meier Estimate; Mice, Knockout; Plaque, Atherosclerotic; Survival Analysis | 2016 |
Atorvastatin Upregulates the Expression of miR-126 in Apolipoprotein E-knockout Mice with Carotid Atherosclerotic Plaque.
Topics: Animals; Apolipoproteins E; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Plaque, Atherosclerotic; Random Allocation; Up-Regulation | 2017 |
Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice.
Topics: Animals; Aorta; Apolipoproteins E; Atorvastatin; Blotting, Western; Down-Regulation; Endoplasmic Reticulum Stress; Homocysteine; Hyperhomocysteinemia; Macrophages; Male; Matrix Metalloproteinase 9; Methionine; Mice; Mice, Knockout; Plaque, Atherosclerotic; RAW 264.7 Cells; Real-Time Polymerase Chain Reaction; Thapsigargin; Tumor Necrosis Factor-alpha | 2016 |
[Expression of cyclophilin A/CD147 in carotid atherosclerotic plaque and the intervention of atorvastatin].
Topics: Animals; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, Dietary; Cyclophilin A; Macrophages; Male; Plaque, Atherosclerotic; Rabbits; Random Allocation; Thrombosis; Triglycerides | 2016 |
Atorvastatin attenuates p‑cresyl sulfate‑induced atherogenesis and plaque instability in ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; Collagen; Cresols; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Sulfuric Acid Esters; Vascular Cell Adhesion Molecule-1 | 2016 |
Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect.
Topics: Atorvastatin; Cell Differentiation; Chaperonin 60; Dendritic Cells; Endarterectomy, Carotid; Extracellular Signal-Regulated MAP Kinases; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukin-17; Interleukin-1beta; Interleukin-6; Lipoproteins, LDL; Lymphocyte Activation; MicroRNAs; Mitochondrial Proteins; Molecular Chaperones; Nuclear Receptor Subfamily 1, Group F, Member 3; Phosphorylation; Plaque, Atherosclerotic; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; T-Box Domain Proteins; T-Lymphocytes; Th1 Cells; Th17 Cells; Tumor Necrosis Factor-alpha | 2016 |
Concise biomarker for spatial-temporal change in three-dimensional ultrasound measurement of carotid vessel wall and plaque thickness based on a graph-based random walk framework: Towards sensitive evaluation of response to therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Middle Aged; Plaque, Atherosclerotic; Ultrasonography | 2016 |
NaoXinTong Enhances Atorvastatin-induced Plaque Stability While Ameliorating Atorvastatin-induced Hepatic Inflammation.
Topics: Animals; Atorvastatin; Drug Synergism; Drug Therapy, Combination; Drugs, Chinese Herbal; Hepatitis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic | 2017 |
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome | 2011 |
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Avena; beta-Glucans; Blood; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fiber; Eating; Female; Heptanoic Acids; Intestinal Absorption; Lipids; Liver; Mice; Mice, Inbred Strains; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2011 |
[Subclinical carotid atherosclerosis in patients with familial combined hyperlipidemia. Two years follow-up after treatment with high doses of atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Statistics, Nonparametric; Ultrasonography | 2012 |
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers, Pharmacological; Blood; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Endoglin; Female; Heptanoic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Sinus of Valsalva; Smad1 Protein; Vascular Endothelial Growth Factor A | 2011 |
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin.
Topics: Animals; Apolipoproteins B; Atorvastatin; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver X Receptors; Macrophages; Multimodal Imaging; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Rabbits; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color | 2012 |
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study.
Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum | 2013 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |